Geoffrey Parker Joins Sunesis' Board
This article was originally published in Scrip
Executive Summary
Sunesis Pharmaceuticals Inc., a company focused on oncology therapeutics, has appointed Geoffrey Parker to its board of directors. Parker brings more than 30 years' of finance and leadership experience to the board and most recently was executive vice president and chief financial officer of Anacor Pharmaceuticals Inc. Parker also has experience working with life sciences companies in various capacities at Goldman Sachs, leading the firm's West Coast healthcare investment banking practice for 12 years. Furthermore, Helen Kim has stepped down from her position as a director.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.